BSc (Microbiology) University of Cape Town, South Africa 1988 BSc (Hons) University of Stellenbosch, South Africa 1989 MSc University of Stellenbosch, South Africa 1993 PhD (rer med) Charite – Campus Benjamin Franklin, Berlin, Germany 1997 – 2000

Development and validation of tumour models for the preclinical evaluation of novel anticancer therapeutics Genetically modified models over-expressing the target at relevant possibly clinical levels Expression and purification of the target enzymes for in vitro high throughput screening of lead compounds

Vinader V, Sadiq M, Sutherland M, Huang M, Loadman PM, Elsalem L, Shnyder SD, Cui H, Afarinkia K, Searcey M, Patterson L, Pors K. 2015. Probing cytochrome P450-mediated activation with a truncated azinomycin analogue. Med Chem Commun.6: 187-191 Bachran C, Bachran S, Sutherland M, Bachran D, Fuchs K. 2014. Preclinical studies of saponins for tumor therapy. Recent advances in Medicinal Chemistry. 1:272-302 Al-Saraireh YM, Sutherland M, Springett BR, Freiberger F, Ribeiro Morais G, Loadman PM, Errington RJ, Smith PJ, Fukuda M, Gerardy-Schahn R, Patterson LH, Shnyder SD, Falconer RA. 2013. Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration. PLoS One. 8:e73366 Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K. 2013. Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity. J. Med. Chem. 56(15):6273-6277 Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH. 2013. Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human bladder cancer. Mol. Cancer Ther. 12(1):27-37 Sutherland M, Shnyder SD, Gordon A, Patterson LH and Sheldrake HM. 2012. RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects. Cancers. 4:1106-1145. ISSN 2072-6694 Pors, K., Loadman, P.M., Shnyder, S.D., Sutherland, M., Sheldrake, H.M., Guino, M., Kiakos, K., Hartley, J.A., Searcey, M., "Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity," Chem Commun (Camb). (2011) Nov 28;47(44):12062-4. Epub 2011 Oct 14. PubMed PMID: 22002321 Bachran, C., Schneider, S., Riese, S.B., Bachran, D., Urban, R., Schellmann, N., Zahn, Sutherland, M. and Fuchs, H. (2011) "A lysine-free mutant of epidermal growth factor as targeting moiety of a targeted toxin," Life Sciences 88:226-232 Bachran, C., Dürkop, H., Sutherland, M., Bachran, D., Muller, C., Weng, A., Melzig, M.F. and Fuchs, H. (2009) "Inhibition of tumour growth by targeted toxins in mice is dramatically improved by Saponinum Album in a synergistic way," J Immunother 32(7):713-725 Sutton C.W, Sutherland M, Shnyder S, Patterson L.H. 2010, Improved preparation and detection of cytochrome P450 isoforms using MS methods. Proteomics 2010 Jan (2):327-31 Fuchs H, Bachran C, Li T, Heisler I, Durkop H, and Sutherland M. 2007, A Cleavable Molecular adapter reduces side effects and concomitantly enhances efficacy in tumour treatment by targeted toxins in mice. J. Control release 117 (3):342-350. Bachran C, Sutherland M, Heisler I, Hebestreit P, Melzig MF and Fuchs H. 2006. The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin?s structure. Experimental Biology and Medicine. 231(4): 412-420. Fuchs H, Bachran C, Heisler I and Sutherland M. 2005. A closer look at protein transduction domains as a tool in drug delivery. Current Nanosciences 1(2):117-124. Bachran C, Heisler I, Fuchs Hand, Sutherland M. 2005. Influence of protein transduction domains on target-specific chimeric proteins. Biochem Biophys Res Commun. 337(2):602-609. Heisler I, Keller J, Tauber R, Sutherland M and Fuchs H. 2003. A cleavable adapter to reduce non-specific cytotoxicity of recombinant immunotoxins. Int. J. Cancer. 103(2):277-282.